SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

• María Martínez-García ^[1] ; Sonia Servitja Tormo ^[1] ; Noelia Vilariño Quintela ^[2] ; Ana Arance Fernández ^[6] ; Alfonso Berrocal Jaime ^[3] ; Blanca Cantos Sánchez de Ibargüen ^[4] ; Sonia Del Barco Berrón ^[7] ; Rosario García Campelo ^[5] ; Regina Gironés Sarrió ^[8] ; Juan Manuel Sepúlveda-Sánchez ^[9]
  1. [1] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  2. [2] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  3. [3] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  4. [4] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  5. [5] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  6. [6] Medical Oncology Department, Hospital Clínic, Barcelona, Spain
  7. [7] Medical Oncology Department, Hospital Universitari Dr. Josep Trueta, ICO, Girona, Spain
  8. [8] Medical Oncology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
  9. [9] Medical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 4 (April), 2022, págs. 703-711
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the blood–brain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.